<DOC>
	<DOCNO>NCT01206582</DOCNO>
	<brief_summary>This study design learn hemin increase production heme oxygenase 1 improve gastric ( stomach ) empty symptom diabetic patient slow gastric emptying ( gastroparesis ) .</brief_summary>
	<brief_title>A Pilot Study Hemin Therapy Gastroparesis ( Diabetes Mellitus )</brief_title>
	<detailed_description>Therapeutic option management diabetic gastroparesis limit . Failure maintain upregulation heme oxygenase 1 ( HO1 ) lead loss interstitial cell Cajal delay gastric empty diabetic non-obese diabetic mouse . HO1 enzyme protects cell physical , chemical , biologic stress . In mice diabetes slow gastric emptying , hemin increase HO-1 activity improve gastric empty . Hemin produce red blood cell approve Food Drug Administration treat acute porphyria , inherited condition cause enzyme deficiency . Hemin approve Food Drug Administration treat gastroparesis . In study subject randomize intravenous hemin , prepared albumin , albumin alone . After infusion day 1 , 3 , 7 , weekly infusion administer 7 week . Assessments include blood test HO1 protein enzyme activity level , gastric empty 13^C-spirulina breath test , autonomic function ( baseline end ) , gastrointestinal symptom every 2 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Gastroparesis</mesh_term>
	<criteria>Where relevant ( i.e. , ensure safety ) , inclusion exclusion criterion similar recently complete trial hemin therapy myelodysplastic syndrome Rush University , Chicago ( http : //clinicaltrials.gov/ct2/show/NCT00467610 ) . Upper gastrointestinal symptom satisfy criterion postprandial distress syndrome vomit last 3 month symptom onset least 6 month prior diagnosis At least moderately severe symptom manifest total symptom score 2.5 high Gastroparesis Cardinal Symptom Index ( GCSI ) 21 Delayed gastric empty ( i.e , &lt; 40 % empty 2 and/or &lt; 90 % empty 4 hour scintigraphy ) No structural cause symptom endoscopy within past 12 month Patient must platelet count &gt; 50,000/microliters absolute neutrophil count ( ANC ) &gt; 500/microliters . Patient must adequate hepatic renal function , define serum bilirubin , serum glutamicoxaloacetic transaminase ( SGOT ) , serum glutamate pyruvate transaminase ( SGPT ) ≤ 2 time upper limit normal ( ULN ) , creatinine ≤ 1.5 time ULN . Able provide write informed consent participate study If female : Either childbearing potential , defined postmenopausal least 1 year surgically sterile ( bilateral tubal ligation , bilateral oophorectomy hysterectomy ) , childbearing potential , must comply effective method birth control acceptable investigator study ( oral contraceptive , DepoProvera , intrauterine device barrier method ) Patient breastfeed . Patient childbearing potential must negative urine serum pregnancy test screening period . History allergic reaction significant sensitivity Panhemantin ® Patients take used investigational drug device 30 day prior screen Predominant symptom epigastric pain rumination syndrome Structural cause symptom recent endoscopy Patients preexist blood coagulation abnormalities Patients previously document renal impairment define 150 mmol/L 1.7 mg/dL serum creatinine Previous gastric intestinal surgery patient enteral feed tubes and/or venting/feeding gastrostomy eligible provide comply study requirement . Tube feed stop 24 hour gastric empty study Current use narcotic , anticholinergic agent ( e.g. , hyoscyamine , belladonna ) , anticoagulant ( e.g. , warfarin ) erythromycin . Gastrointestinal prokinetic drug ( eg metoclopramide , domperidone ) may continue stable dose throughout study History preexist medical condition , opinion investigator , interfere participation study . History venous thrombosis hypercoagulable state Poor peripheral venous access , central venous access available Uncontrolled active infection Any condition prior therapy , opinion investigator , would make patient unsuitable study . Known intolerance allergy egg Screening weight great 130 kg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>